Asia tech stocks slide tracking Wall St losses amid AI doubts, govt. uncertainty
Abbott Laboratories (NYSE:ABT)’ stock soared to a 52-week high this week, with shares reaching a price level of $134.46. The healthcare giant, with a market capitalization of $233 billion and known for its diversified medical devices and health care products, has demonstrated remarkable strength with a 20.75% return over the past six months. According to InvestingPro analysis, the company appears to be trading slightly above its Fair Value. Investors have been buoyed by the company’s consistent performance and strategic growth initiatives, which have culminated in a 12.83% gain over the past year. This surge in stock value reflects the market’s confidence in Abbott’s robust product pipeline and its ability to navigate the complex healthcare landscape effectively. InvestingPro data reveals the company has maintained dividend payments for 55 consecutive years, with a current yield of 1.77%. For deeper insights and 12 additional exclusive ProTips about Abbott, explore the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Abbott Laboratories has been the focus of several analyst upgrades. Barclays (LON:BARC) raised its price target for Abbott Labs to $158, citing an improved financial outlook and the company’s updated guidance for earnings per share growth. Despite challenges from foreign exchange rates and tax rate increases, Abbott’s management expects a 10% EPS growth by 2025. Bernstein also increased its price target to $138, driven by strong performance in Abbott’s Medical (TASE:BLWV) Devices segment, which saw significant growth in Continuous Glucose Monitoring and Structural Heart products. UBS followed suit, adjusting its price target to $148, reflecting confidence in Abbott’s core business strength and margin expansion. Stifel raised its target to $135, acknowledging Abbott’s 10.1% organic revenue growth for Q4 2024, although total revenues slightly missed expectations due to lower Covid testing sales. Abbott’s Medical Device division, however, showed robust performance with a 14% year-over-year sales increase, particularly in the Structural Heart and Diabetes sub-segments. These analyst updates underscore a positive outlook for Abbott, with several firms maintaining strong ratings on the stock.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.